BeiGene Ltd., co-founded in 2010 by John V. Oyler and Dr. Xiaodong Wang in Beijing, China , has evolved into a global biotechnology company . The company is dedicated to developing innovative and affordable cancer treatments . With a mission to expand access to high-quality therapies worldwide , BeiGene has grown to employ over 9,000 individuals across five continents . In 2025, the company announced plans to rebrand as BeOne Medicines, reflecting its commitment to uniting the global community in the fight against cancer.
Operating on a global scale, BeiGene has established administrative offices in key locations, including Basel, Switzerland; Cambridge, Massachusetts; and Beijing, China . The company's research and development efforts are supported by state-of-the-art manufacturing facilities that comply with FDA and European regulatory standards . This extensive infrastructure enables BeiGene to conduct over 170 clinical trials worldwide, involving more than 25,000 patients.
BeiGene's portfolio includes FDA-approved medications such as BRUKINSA® (zanubrutinib), a Bruton's tyrosine kinase inhibitor, and TEVIMBRA® (tislelizumab), an anti-PD-1 antibody . The company is also advancing a broad pipeline of over 40 clinical and commercial stage assets targeting various cancers . Collaborations with global partners like Amgen and Novartis have further expanded BeiGene's reach and capabilities in oncology research and development.
BeiGene has continued to strengthen its global presence . The company has also made strategic decisions to streamline its pipeline, including the discontinuation of the clinical development program for ociperlimab (BGB-A1217), an anti-TIGIT antibody . These initiatives underscore BeiGene's commitment to delivering innovative cancer treatments to patients worldwide.